Faron Pharmaceuticals
Ltd.
("Faron"
or "the Company")
Faron announces Capital
Markets Day to be held on 22 October 2024
Press release, 7 October 2024
TURKU, FINLAND - Faron
Pharmaceuticals Ltd. (AIM: FARN, First North: FARON),
a clinical-stage biopharmaceutical company focused
on tackling cancers via novel
immunotherapies,
today announces that it will host a Capital Markets Day for
investors, analysts and media on Tuesday, 22 October 2024 at 08:00
am (EDT) / 13:00 pm (BST) / 15:00 pm (EEST). Speakers include Dr.
Mika Kontro, MD, PhD, Associate Professor at the University
of Helsinki, Mr. Ralph Hughes, MSc, BSc, Senior Vice President
at PharmaVentures and members of Faron's senior management
team.
The agenda is as follows:
·
Opening remarks
·
Faron's strategy and key focus areas
- Dr. Juho Jalkanen, MD, PhD, CEO
·
BEXMAB clinical data - Dr. Mika Kontro, MD, PhD,
principal investigator of the BEXMAB trial
·
BEXMAB MDS market assessment - Mr. Ralph Hughes,
MSc, BSc
·
Faron's development plan for solid tumors - Dr. Petri Bono, MD,
PhD, CMO
·
Who benefits from bexmarilimab and why - Future
Addressable Markets - Dr. Maija Hollmén,
PhD, CSO
·
Q&A session
·
Closing remarks
As part of the event, Juho Jalkanen,
CEO of Faron, will discuss Faron's strategy and key focus areas for
the coming years. Dr. Kontro will
share updated survival data from the
ongoing BEXMAB Phase I/II
trial. Mr. Hughes will
present the results of recently conducted market research in MDS.
Dr. Bono will provide Faron's development plan for solid tumours,
discuss bexmarilimab's
further potential as first-in-class
immune-oncological treatment and introduce the Company's new
Scientific Advisory Board (SAB).
"I am delighted to be hosting
this Capital Markets Day with our invited speakers and
members of Faron's senior management team who will provide important insights into the
recent developments and further plan
to bring the promise of
immunotherapy to a broader patient group," said Dr.
Juho Jalkanen, Chief
Executive Officer of Faron. "In
addition to providing the latest BEXMAB survival update, we will
present the clinical development plan for bexmarilimab in solid tumors. The
event will also feature an introduction to our new Scientific
Advisory Board with world-leading clinical investigators," said Dr.
Petri Bono, Chief Medical Officer at Faron.
The event will be held as a live
hybrid event. It will begin at 08:00 am (EDT) / 13:00 pm (BST) /
15:00 pm (EEST) on Tuesday, October 22, 2024. The duration of the
event will be some 2.5 hours.
Webcast registration link: https://faron.videosync.fi/cmd-2024
Live participation
In addition to the webcast, there
are a limited number of seats available to attend the
Capital Markets Day at Eliel in Sanomatalo at Töölönlahdenkatu 2, Helsinki. To
register, please contact
investor.relations@faron.com no
later than 2:00 pm (EEST)
on Friday, 18
October 2024. Please note that places are
limited, and you will receive a separate email if you get a seat
confirmed.
A link to a recording of this
Capital Markets Day will
be made available on the "Investors" section on Faron's website at:
https://www.faron.com/investors.
For
more information please contact:
ICR Consilium
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Cairn Financial Advisers LLP,
Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213
0880
Peel Hunt LLP, Broker
Christopher Golden, James
Steel
Phone: +44 (0) 20 7418
8900
Sisu Partners Oy, Certified Adviser
on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555
4727
Jukka Järvelä
Phone: +358 (0)50 553
8990
About BEXMAB
The BEXMAB study is an open-label
Phase I/II clinical trial investigating bexmarilimab in combination with
standard of care (SoC) in the aggressive hematological malignancies
of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
The primary objective is to determine the safety and tolerability
of bexmarilimab in
combination with SoC (azacitidine) treatment. Directly targeting
Clever-1 could limit the replication capacity of cancer cells,
increase antigen presentation, ignite an immune response, and allow
current treatments to be more effective. Clever-1 is highly
expressed in both AML and MDS and associated with therapy
resistance, limited T cell activation and poor outcomes.
About bexmarilimab
Bexmarilimab is Faron's wholly owned, investigational immunotherapy
designed to overcome resistance to existing treatments and optimize
clinical outcomes, by targeting myeloid cell function and igniting
the immune system. Bexmarilimab binds to Clever-1, an
immunosuppressive receptor found on macrophages leading to tumor
growth and metastases (i.e. helps cancer evade the immune system).
By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor
microenvironment, reprogramming macrophages from an
immunosuppressive (M2) state to an immunostimulatory (M1) one,
upregulating interferon production and priming the immune system to
attack tumors and sensitizing cancer cells to standard of
care.
About Faron Pharmaceuticals
Ltd
Faron (AIM: FARN, First North:
FARON) is a global, clinical-stage biopharmaceutical company,
focused on tackling cancers via novel immunotherapies. Its mission
is to bring the promise of immunotherapy to a broader population by
uncovering novel ways to control and harness the power of the
immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1
humanized antibody, with the potential to remove immunosuppression
of cancers through reprogramming myeloid cell function.
Bexmarilimab is being
investigated in Phase I/II clinical trials as a potential therapy
for patients with hematological cancers in combination with other
standard treatments. Further information is available at
www.faron.com.
